NCT03110978 2026-04-16
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
29 trialsNCT05470595 2026-04-15
LCNEC-ALPINE
Technische Universität Dresden
Phase 2 Active not recruiting
NCT06941480 2026-04-14
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Memorial Sloan Kettering Cancer Center
Phase 1 Not yet recruiting
NCT06893783 2026-04-13
DeLLight
Asan Medical Center
Phase 2 Recruiting
NCT04069299 2026-03-31
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
H. Lee Moffitt Cancer Center and Research Institute
Completed
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07458906 2026-03-09
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
The First Affiliated Hospital of Xiamen University
Phase NA Recruiting
NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
NCT06937905 2026-02-11
TARLANEC
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Recruiting
NCT07337447 2026-01-13
REWENEC 01
Hospices Civils de Lyon
Phase 2 Not yet recruiting
NCT03290079 2025-12-22
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05064150 2025-12-18
NET-PRO
University of Iowa
Active not recruiting
NCT06889493 2025-12-17
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Phase 1 Recruiting
NCT04701307 2025-12-15
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06333314 2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2 Recruiting
NCT05337735 2025-10-09
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT04325425 2025-09-30
FOLFIRINEC
Centre Hospitalier Universitaire Dijon
Phase 2 Recruiting
NCT07192991 2025-09-25
NECTARINE
Latin American Cooperative Oncology Group
Not yet recruiting
NCT07156019 2025-09-04
Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT02820857 2025-09-03
BEVANEC
Hospices Civils de Lyon
Phase 2 Completed
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT01876771 2025-08-08
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT05262556 2025-08-07
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT01879657 2025-08-06
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
Radio Isotope Therapy of America
Phase NA Completed
NCT05420636 2025-07-30
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Fox Chase Cancer Center
Phase 2 Terminated
NCT04268121 2025-07-23
NEONEC
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT07014540 2025-06-11
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
Beijing GoBroad Hospital
Phase 4 Not yet recruiting
NCT00113360 2025-05-01
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed